Vetoquinol (XPAR:VETO) Cyclically Adjusted PB Ratio: (As of Sep. 20, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XPAR:VETO Vetoquinol SA XPAR:VETO
91 GF Score
Price €73.60
GF Value €80.88
Valuation Fairly Valued
! 1 Warning Sign
View Full Analysis

What is Vetoquinol Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Vetoquinol  (XPAR:VETO) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Vetoquinol Cyclically Adjusted PB Ratio Related Terms


Vetoquinol Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for Vetoquinol's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vetoquinol Cyclically Adjusted PB Ratio Chart

Vetoquinol Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.60 2.72 2.88 1.96 2.06

Vetoquinol Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.57 2.00 1.91 2.10 1.70

XPAR:VETO vs ZTS, UTHR, VTRS: Cyclically Adjusted PB Ratio Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Vetoquinol's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vetoquinol Cyclically Adjusted PB Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Vetoquinol's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Vetoquinol's Cyclically Adjusted PB Ratio falls into.


XPAR:VETO
91GF Score
Vetoquinol SA XPAR:VETO
Cyclically Adjusted PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vetoquinol Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Vetoquinol's Cyclically Adjusted Book per Share for the fiscal year that ended in Dec25 is calculated as:

For example, Vetoquinol's adjusted Book Value per Share data for the fiscal year that ended in Dec25 was:

Adj_Book=Book Value per Share/CPI of Dec25 (Change)*Current CPI (Dec25)
=50.89/120.8900*120.8900
=50.890

Current CPI (Dec25) = 120.8900.

Vetoquinol Annual Data

Book Value per Share CPI Adj_Book
201612 26.690 100.650 32.057
201712 28.316 101.850 33.609
201812 30.664 103.470 35.827
201912 32.622 104.980 37.566
202012 31.441 104.960 36.213
202112 37.315 107.850 41.827
202212 40.963 114.160 43.378
202312 44.551 118.390 45.492
202412 48.810 119.950 49.193
202512 50.890 120.890 50.890

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Vetoquinol (XPAR:VETO) Overvalued in 2026?

Based on GuruFocus' analysis, Vetoquinol stock appears to be undervalued. The current stock price of €73.60 is trading 9% below its estimated GF Value™ of €80.88. GuruFocus considers Vetoquinol to be Fairly Valued.

Key valuation signals for XPAR:VETO:

  • Cyclically Adjusted PB Ratio:
  • GF Value™: €80.88 vs. price of €73.60 (9% below fair value)
  • GF Score™: 91/100 with 1 warning sign

No single metric tells the full story. See the XPAR:VETO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Vetoquinol Business Description

Other Exchanges 0O1O:UK8JM:Germany
Address Magny-Vernois, BP 189, Lure cedex, FRA, 70204
Vetoquinol SA operates is a France-based firm serving in the healthcare market. Its focus lies on developing and marketing veterinary drugs mainly in the European region and to a certain extent in America and Asia. Its portfolio of drugs entails anti-infectives, anti- pain inflammatory drugs, cardiovascular and nephrology treatment intended mainly for pets and livestock.
91GF Score

Get the complete analysis for XPAR:VETO

Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€73.60
Price
€80.88
GF Value